Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations by Brooke E. Wilson, Alexandra Desnoyers, Michelle B. Nadler, Ariadna Tibau, Eitan Amir

Get full text

A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time by Brooke E. Wilson, Alexandra Desnoyers, Laith Al-Showbaki, Michelle B. Nadler, Eitan Amir

Get full text

Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer by Coralea Kappel, Mitchell J. Elliott, Vikaash Kumar, Michelle B. Nadler, Alexandra Desnoyers, Eitan Amir

Get full text

Magnitude of effect and sample size justification in trials supporting anti-cancer drug approval by the US Food and Drug Administration by Michelle B. Nadler, Brooke E. Wilson, Alexandra Desnoyers, Consolacion Molto Valiente, Ramy R. Saleh, Eitan Amir

Get full text

Perceived guideline clarity impacts guideline-concordant care for breast cancer screening in women age 40–49 by Michelle B. Nadler, Ann Marie Corrado, Brooke E. Wilson, Alexandra Desnoyers, Eitan Amir, Noah Ivers, Laura Desveaux

Get full text

Management of Oligometastatic Breast Cancer: An Expert Committee’s Opinion by Dominique Leblanc, Guy Cantin, Alexandra Desnoyers, Jean Dufresne, Giuseppina Laura Masucci, Valérie Panet-Raymond, Éric Poirier, Sara Soldera, Isabelle Gingras

Get full text